癌症是國人的十大死因之首,且90%的癌症病人因癌轉移而死亡,尋找癌轉移的基因標的, 能夠提升有效篩檢與預測癌轉移的可能性,以癌化(tumorigenesis) 與轉移(metastasis) 為平行演化為出發點,利用高通量生物晶片資料,結合有轉移能力的惡性腫瘤、不會轉移的良性腫瘤,子宮內膜異位到卵巢的細胞、正常的子宮內膜細胞,找到428個促癌轉移基因與548 個抑癌轉移基因,再與正常細胞組織的基因表現量微陣列圖譜進行比對,發現176 個促癌轉移基因與248 個抑癌轉移基因分別高表現和低表現在白血球相關細胞組織,為驗證這些候選基因,也將進行功能性試驗(functional assay),包括細胞癒合實驗(In vitro migration assay) 和細胞侵襲實驗(In vitro invasion assay),鑑定出真正決定性的目標基因。對於未來的研究,可針對轉移相關的目標基因進行阻斷,研發標靶藥物達到抑制癌症轉移、降低死亡率的目的。
Cancer death proceeded to the leading cause of death and metastasis accounts for 90% of cancer deaths. Finding the set of metastatic biomarkers is prerequisite for increasing effective screening and prognostic prediction. Based on the theory that tumorigenesis and metastasis are evolved in parallel, we obtained 428 Metastasis Promoting Genes (MPG) and 548 Metastasis Suppressor Genes (MSG) by meta-data analysis from metastatic tumors, benign tumors, ectopic ovarian endometrium, eutopic endometrium microarray data. Furthermore,using the microarray data of the normal tissues, we obtained 176 MPG highly expression and 248 MSG low expression in leukocyte-related tissues. To validate those candidate genes, we will carry out the functional assay including in vitro migration assay and in vitro invasion assay. In the future, those Metastatic Related Genes that could effectively differentiate the potential tendency for tumor to metastasize are potential drug targets to facilitate the therapeutic lead compound development.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。